700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Robert MacLaren is Professor of Ophthalmology at the University of Oxford, Consultant Ophthalmologist at the Oxford Eye Hospital, Honorary Professor of Ophthalmology at the UCL Institute of Ophthalmology, Honorary Consultant Vitreoretinal Surgeon at Moorfields Eye Hospital, Faculty Member and Founding Theme Leader of the Moorfields-UCL Institute of Ophthalmology Biomedical Research Centre and an NIHR Senior Investigator. He is also a Fellow of the Royal College of Ophthalmologists, Fellow and former King James IV Professor of Surgery at the Royal College of Surgeons of Edinburgh, Fellow of the Higher Education Academy, Bodley Fellow of Merton College Oxford and Civilian Consultant Advisor to the Royal Navy. He has been a recipient of the ARVO Camras Award for Translational Research, the RP Fighting Blindness Scientist of the Year Award and the Euretina Innovation Award. Together with the University of Oxford in 2014 he co-founded Nightstar, a biotechnology company based at the Wellcome Trust in London and which has been established to develop further gene therapy treatments for patients with retinal diseases.
His clinical and laboratory research is dedicated to finding new treatments for blindness, particularly in patients with incurable retinal diseases, using stem cell-based approaches, gene therapy or electronic retinas. His laboratory is also developing new techniques for cataract and retinal surgery.
Michelle E McClements, Peter Charbel Issa, Véronique Blouin and Robert E MacLaren
Research Article: J Genet Syndr Gene Ther 2016, 7: 311